Potent anticancer activity of pyrrolidine dithiocarbamate-copper complex against cisplatin-resistant neuroblastoma cells

Haiyuan Zhang, Jiu Sheng Wu, Fangyu Peng

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Effective drugs are urgently needed for the treatment of advanced neuroblastoma refractory to conventional chemotherapy. Pyrrolidine dithiocarbamate (PDTC) is a copper-binding ligand, which showed cytotoxicity on many human tumor cells after binding with copper ions. In this study, we synthesized a copper-PDTC complex, which was characterized as a Cu(PDTC)2 complex, with elemental analyses (Fourier transform infrared, electrospray ionization mass spectra, and ultraviolet-visible spectroscopy). The Cu(PDTC)2 complex suppressed the proliferation of BE(2)C cells, a human neuroblastoma cell line, with an IC50 of 8.0 μmol/l, which was more potent than cisplatin (IC50 of 80 μmol/l). Treatment of BE(2)C cells with the Cu(PDTC)2 complex caused the S-phase arrest of cell cycle progression, cellular apoptosis, and necrosis, and increased the expression of p53 protein. The Cu(PDTC)2 complex holds potential as a new drug for the treatment of refractory neuroblastoma in children.

Original languageEnglish (US)
Pages (from-to)125-132
Number of pages8
JournalAnti-Cancer Drugs
Volume19
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Neuroblastoma
Cisplatin
Copper
Inhibitory Concentration 50
Fourier Analysis
Cell Cycle Checkpoints
S Phase
Pharmaceutical Preparations
pyrrolidine dithiocarbamic acid
Spectrum Analysis
Necrosis
Therapeutics
Ions
Apoptosis
Ligands
Drug Therapy
Cell Line
Neoplasms
Proteins

Keywords

  • Apoptosis
  • Cell cycle
  • Copper
  • Neuroblastoma
  • Pyrrolidine dithiocarbamate

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Potent anticancer activity of pyrrolidine dithiocarbamate-copper complex against cisplatin-resistant neuroblastoma cells. / Zhang, Haiyuan; Wu, Jiu Sheng; Peng, Fangyu.

In: Anti-Cancer Drugs, Vol. 19, No. 2, 02.2008, p. 125-132.

Research output: Contribution to journalArticle

@article{efbcd22115d34cf3b325212f019a7126,
title = "Potent anticancer activity of pyrrolidine dithiocarbamate-copper complex against cisplatin-resistant neuroblastoma cells",
abstract = "Effective drugs are urgently needed for the treatment of advanced neuroblastoma refractory to conventional chemotherapy. Pyrrolidine dithiocarbamate (PDTC) is a copper-binding ligand, which showed cytotoxicity on many human tumor cells after binding with copper ions. In this study, we synthesized a copper-PDTC complex, which was characterized as a Cu(PDTC)2 complex, with elemental analyses (Fourier transform infrared, electrospray ionization mass spectra, and ultraviolet-visible spectroscopy). The Cu(PDTC)2 complex suppressed the proliferation of BE(2)C cells, a human neuroblastoma cell line, with an IC50 of 8.0 μmol/l, which was more potent than cisplatin (IC50 of 80 μmol/l). Treatment of BE(2)C cells with the Cu(PDTC)2 complex caused the S-phase arrest of cell cycle progression, cellular apoptosis, and necrosis, and increased the expression of p53 protein. The Cu(PDTC)2 complex holds potential as a new drug for the treatment of refractory neuroblastoma in children.",
keywords = "Apoptosis, Cell cycle, Copper, Neuroblastoma, Pyrrolidine dithiocarbamate",
author = "Haiyuan Zhang and Wu, {Jiu Sheng} and Fangyu Peng",
year = "2008",
month = "2",
doi = "10.1097/CAD.0b013e3282f2bdff",
language = "English (US)",
volume = "19",
pages = "125--132",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Potent anticancer activity of pyrrolidine dithiocarbamate-copper complex against cisplatin-resistant neuroblastoma cells

AU - Zhang, Haiyuan

AU - Wu, Jiu Sheng

AU - Peng, Fangyu

PY - 2008/2

Y1 - 2008/2

N2 - Effective drugs are urgently needed for the treatment of advanced neuroblastoma refractory to conventional chemotherapy. Pyrrolidine dithiocarbamate (PDTC) is a copper-binding ligand, which showed cytotoxicity on many human tumor cells after binding with copper ions. In this study, we synthesized a copper-PDTC complex, which was characterized as a Cu(PDTC)2 complex, with elemental analyses (Fourier transform infrared, electrospray ionization mass spectra, and ultraviolet-visible spectroscopy). The Cu(PDTC)2 complex suppressed the proliferation of BE(2)C cells, a human neuroblastoma cell line, with an IC50 of 8.0 μmol/l, which was more potent than cisplatin (IC50 of 80 μmol/l). Treatment of BE(2)C cells with the Cu(PDTC)2 complex caused the S-phase arrest of cell cycle progression, cellular apoptosis, and necrosis, and increased the expression of p53 protein. The Cu(PDTC)2 complex holds potential as a new drug for the treatment of refractory neuroblastoma in children.

AB - Effective drugs are urgently needed for the treatment of advanced neuroblastoma refractory to conventional chemotherapy. Pyrrolidine dithiocarbamate (PDTC) is a copper-binding ligand, which showed cytotoxicity on many human tumor cells after binding with copper ions. In this study, we synthesized a copper-PDTC complex, which was characterized as a Cu(PDTC)2 complex, with elemental analyses (Fourier transform infrared, electrospray ionization mass spectra, and ultraviolet-visible spectroscopy). The Cu(PDTC)2 complex suppressed the proliferation of BE(2)C cells, a human neuroblastoma cell line, with an IC50 of 8.0 μmol/l, which was more potent than cisplatin (IC50 of 80 μmol/l). Treatment of BE(2)C cells with the Cu(PDTC)2 complex caused the S-phase arrest of cell cycle progression, cellular apoptosis, and necrosis, and increased the expression of p53 protein. The Cu(PDTC)2 complex holds potential as a new drug for the treatment of refractory neuroblastoma in children.

KW - Apoptosis

KW - Cell cycle

KW - Copper

KW - Neuroblastoma

KW - Pyrrolidine dithiocarbamate

UR - http://www.scopus.com/inward/record.url?scp=37849040263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849040263&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e3282f2bdff

DO - 10.1097/CAD.0b013e3282f2bdff

M3 - Article

C2 - 18176108

AN - SCOPUS:37849040263

VL - 19

SP - 125

EP - 132

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 2

ER -